Sign in

    Lili Nsongo

    Senior Equity Research Analyst at Leerink Partners

    Lili Nsongo, Ph.D., is a Senior Equity Research Analyst at Leerink Partners specializing in genetic medicine and diversified biopharmaceuticals, with a focus on companies such as Arcturus Therapeutics, Voyager Therapeutics, Sensorion SA, and Zai Lab Ltd. Despite a strong scientific background, Nsongo’s analyst performance has lagged, ranking in the bottom decile with a 0% success rate and an average return of -40.81% based on published ratings and price targets. Nsongo joined Leerink Partners before 2024 after earning a doctorate and has since initiated coverage on multiple biotechnology companies, setting notable price targets like $54 for Arcturus Therapeutics in 2025. Nsongo holds a Ph.D. and is FINRA-registered, compliant with relevant securities licensing requirements for equity research analysts.

    Lili Nsongo's questions to Schrodinger (SDGR) leadership

    Lili Nsongo's questions to Schrodinger (SDGR) leadership • Q2 2025

    Question

    Lili Nsongo, on behalf of Mani Faroohar at Leerink Partners, questioned the adoption and growth expectations for the new predictive toxicology feature and asked to quantify the potential for increased usage among existing customers.

    Answer

    CEO Ramy Farid highlighted that the recently launched beta version of the predictive toxicology feature is seeing significant excitement and demand, aligning with the FDA's push to reduce animal testing. CFO Richie Jain added that there is substantial room for growth within existing customers, with a key strategy being the migration of smaller and medium-tier accounts to larger contracts.

    Ask Fintool Equity Research AI